Literature DB >> 12964513

Frequency of lymphadenopathy in rheumatoid arthritis and systemic lupus erythematosus.

M Calgüneri1, M A Oztürk, Z Ozbalkan, A Akdogan, K Ureten, S Kiraz, I Ertenli.   

Abstract

This study aimed to assess the frequency of all palpable lymph nodes during active disease and remission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Hospital records of 100 SLE patients, 100 RA patients, 100 spondyloarthropathy patients, and 150 osteoarthritis patients, treated in our rheumatology department, were evaluated retrospectively. Overall frequencies of enlarged lymph nodes in patients with active RA and SLE were 82% and 69%, respectively. Enlarged lymph nodes associated with RA were mostly located in the axillary region, and in SLE the nodes were smaller and lymphadenopathy was more generalized compared with RA. Palpable lymph nodes disappeared in the majority of patients during remission. Lymphadenopathy was significantly less frequent in patients treated with steroids before admission. Lymph node enlargement is an important physical finding associated with RA and SLE disease activity. Atypical locations and unusually large lymph nodes should raise clinical suspicion of another underlying disease.

Entities:  

Mesh:

Year:  2003        PMID: 12964513     DOI: 10.1177/147323000303100415

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  14 in total

Review 1.  Regulation of Lymph Node Vascular-Stromal Compartment by Dendritic Cells.

Authors:  Dragos C Dasoveanu; William D Shipman; Jennifer J Chia; Susan Chyou; Theresa T Lu
Journal:  Trends Immunol       Date:  2016-09-13       Impact factor: 16.687

2.  CT assessment of axillary lymphadenopathy in patients with rheumatoid arthritis: association with disease activity and severity.

Authors:  Mizue Hasegawa; Fumikazu Sakai; Naoko Konda; Asako Okabayashi; Hideki Katsura; Yohei Seto
Journal:  Rheumatol Int       Date:  2018-02-12       Impact factor: 2.631

Review 3.  Lymph node vascular-stromal growth and function as a potential target for controlling immunity.

Authors:  Fairouz Benahmed; Scott Ely; Theresa T Lu
Journal:  Clin Immunol       Date:  2012-05-11       Impact factor: 3.969

4.  Relationships between Cytokine Levels and Disease Parameters during the Development of a Collagen-induced Arthritis Model in Cynomolgus Macaques (Macaca fascicularis).

Authors:  Eun Wha Choi; Sungjoo Kim
Journal:  Comp Med       Date:  2019-05-08       Impact factor: 0.982

Review 5.  Spectrum of [18F]FDG-PET/CT Findings in Benign Lymph Node Pathology.

Authors:  Merissa N Zeman; Clare Green; Esma A Akin
Journal:  Mol Imaging Biol       Date:  2021-01-29       Impact factor: 3.488

6.  Optical projection tomography reveals dynamics of HEV growth after immunization with protein plus CFA and features shared with HEVs in acute autoinflammatory lymphadenopathy.

Authors:  Varsha Kumar; Susan Chyou; Jens V Stein; Theresa T Lu
Journal:  Front Immunol       Date:  2012-09-07       Impact factor: 7.561

Review 7.  The draining lymph node in rheumatoid arthritis: current concepts and research perspectives.

Authors:  Francesca Benaglio; Barbara Vitolo; Martina Scarabelli; Elisa Binda; Serena Bugatti; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

8.  Reactivation tuberculosis presenting with unilateral axillary lymphadenopathy.

Authors:  Esther Hwang; Janet Szabo; Alex Federman; Laurie R Margolies
Journal:  Radiol Case Rep       Date:  2018-09-15

Review 9.  Lymphatic Function in Autoimmune Diseases.

Authors:  Noa Schwartz; Madhavi Latha S Chalasani; Thomas M Li; Zhonghui Feng; William D Shipman; Theresa T Lu
Journal:  Front Immunol       Date:  2019-03-20       Impact factor: 7.561

10.  Systemic lupus erythematosus and granulomatous lymphadenopathy.

Authors:  Devendra Shrestha; Ajaya Kumar Dhakal; Raj K C Shiva; Arati Shakya; Subhash Chandra Shah; Henish Shakya
Journal:  BMC Pediatr       Date:  2013-11-05       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.